Reuters logo
BRIEF-Benitec Biopharma provides update On Opmd Orphan Disease program
November 27, 2017 / 1:12 PM / 18 days ago

BRIEF-Benitec Biopharma provides update On Opmd Orphan Disease program

Nov 27 (Reuters) - Benitec Biopharma Ltd:

* BENITEC BIOPHARMA PROVIDES UPDATE ON OPMD ORPHAN DISEASE PROGRAM

* BENITEC BIOPHARMA - SUBMITTED APPLICATION WITH U.S. FDA SEEKING ORPHAN DRUG DESIGNATION FOR BB-301 AS A TREATMENT OF OCULOPHARYNGEAL MUSCULAR DYSTROPHY​

* SAYS INTENDS TO FILE AN IND FOR BB-301 IN Q4 OF CALENDAR YEAR 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below